Design Therapeutics vs Larimar Therapeutics
DSGN and LRMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DSGN and LRMR compare
Design Therapeutics is the larger company, worth 2.4 times as much as Larimar Therapeutics ($662M against $280M).
Design Therapeutics scores higher on the StockData Score (7 against 5 for Larimar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DSGN | LRMR |
|---|---|---|
| Size and price | ||
| Market cap | $662M | $280M |
| Share price | $10.58 | $2.70 |
| Change, 1 year | 36.3% | −25.6% |
| Change, 5 years | −48.4% | −73.7% |
| Beta (5Y) | 1.69 | 1.33 |
| Employees | 54 | 71 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.3× | 2.2× (better) |
| FCF yield | −9.0% | – |
| Profitability | ||
| Return on equity | −36.9% (better) | −140% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.78 (better) | 4.70 |
| Altman Z-score | 24.76 (better) | −2.43 |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Buyback yield | −9.4% | – |
| Shareholder yield | −9.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 69.2% | 91.9% |
| Held by insiders | 21.2% | 66.3% |
| Insider net buying, 12 months | – | $25.7M |
| Short interest, % of float | 12.8% | 30.1% |
Go deeper
- DSGN stock overview
- DSGN income statement
- DSGN valuation and score
- LRMR stock overview
- LRMR income statement
- LRMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.